Neoadjuvant therapy of juvenile angiofibroma of the nasopharynx and base of the skull with good clinical outcome (clinical case)

Cover Page

Cite item

Full Text

Abstract

Juvenile nasopharyngeal angiofibroma is a benign, highly vascularized tumor that occurs mainly in children and young men of pubertal age 9-19 years old. Often manifested by difficulty in nasal breathing and nosebleeds. We report a 16-year-old boy with complaints of a complete absence of nasal breathing, nosebleeds, snoring, nasality, exophthalmos on the right side, visual impairment. undergoing therapeutic treatment for rhinosinusitis and adenoid vegetations for 5 months and an unsuccessful attempt at adenotomy in history. When contacting the Department of Oncology and Pediatric Surgery Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology according to imaging with contrast enhancement juvenile angiofibroma of the nasopharynx IVA stage to Fisch-Andrews with a 30 % increase in volume in 2 months. The patient was initiated on neoadjuvant therapy Sirolimus as part of a pilot phase of a prospective clinical trial. After 9 months of taking the drug, there is a reduction in the tumor by 37 %, restoration of vision, clinical and radiological improvement.

About the authors

I. N. Vorozhtsov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Author for correspondence.
Email: dr.vorozhtsov@gmail.com
ORCID iD: 0000-0002-3932-6257

Igor N. Vorozhtsov.

1 Samora Mashela St., Moscow 117198

Russian Federation

N. S. Grachev

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Medical Institute of Continuing Education of the Russian Biotechnological University

Email: fake@neicon.ru
ORCID iD: 0000-0002-4451-3233

1 Samora Mashela St., Moscow 117198; 11 Volokolamskoye Shosse, Moscow 125080

Russian Federation

E. I. Chechev

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Email: fake@neicon.ru
ORCID iD: 0000-0002-2607-9795

1 Samora Mashela St., Moscow 117198

Russian Federation

A. S. Krasnov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology

Email: fake@neicon.ru
ORCID iD: 0000-0003-1099-9332

1 Samora Mashela St., Moscow 117198

Russian Federation

References

  1. Chandler J.R., Moskowitz L., Goulding R., Quencer R.M. Nasopharyngeal angiofibromas: staging and management. Ann Otol Rhinol Laryngol 1984;93(4 Pt. 1):322-9. doi: 10.1177/000348948409300408
  2. Krasnov A.S., Grachev N.S., Vorozhtsov I.N., Tereshchenko G.V. Juvenile nasopharyngeal angiofibroma. Voprosy gematologii/ onkologii i immunopatologii v pediatrii = Pediatric Hematology/ Oncology and Immunopathology 2020;19(4):185-97. (In Russ.). doi: 10.24287/1726-1708-2020-19-4-185-197
  3. Patrocmio J.A., Patrodnio L.G., Borba B.H.C. et al. Nasopharyngeal angiofibroma in an elderly woman. Am J Otola¬ryngol 2005;26(3):198-200. doi: 10.1016/j.amjoto.2004.08.012
  4. Thakar A., Hota A., Bhalla A.S. et al. Overt and occult vidian canal involvement in juvenile angiofibroma and its possible impact on recurrence. Head Neck 2016;38:E421-5. doi: 10.1002/hed.24012
  5. Nicolai P., Berlucchi M., Tomenzoli D. et al. Endoscopic surgery for juvenile angiofibroma: when and how. Laryngoscope 2003;113(5):775-82. doi: 10.1097/00005537-200305000-00003
  6. Onerci M., Gumus K., Cil B., Eldem B. A rare complication of embolization in juvenile nasopharyngeal angiofibroma. Int J Pediatr Otorhinolaryngol 2005;69(3):423-8. doi: 10.1016/j.ijporl.2004.10.015
  7. Sun X.C., Wang D.H., Yu H.P. et al. Analysis of risk factors associated with recurrence of nasopharyngeal angiofibroma. J Otolaryngol Head Neck Surg 2010;39(1):56-61. doi: 10.2310/7070.2009.080220
  8. Mann W.J., Jecker P., Amedee R.G. Juvenile angiofibromas: changing surgical concept over the last 20 years. Laryngoscope 2004;114(2):291-3. doi: 10.1097/00005537-200402000-00020
  9. Schreiber A., Bertazzoni G., Ferrari M. et al. Management of persistent juvenile angiofibroma after endoscopic resection: analysis of a single institution series of 74 patients. Head Neck 2019;41(5):1297-303. doi: 10.1002/hed.25555
  10. Grachev N.S., Vorozhtsov I.N., Frolov S.V., Polev G.A. Surgical treatment of juvenile nasopharyngeal angiofibroma. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatria. Journal named after G. N. Speransky 2019;98(4):205-9. (In Russ.). doi: 10.24110/0031-403X-2019-98-4-205-209
  11. Mallick S., Benson R., Bhasker S., Mohanti B.K. Long-term treat¬ment outcomes of juvenile nasopharyngeal angiofibroma treated with radiotherapy. Acta Otorhinolaryngol Ital 2015;35(2):75-9.
  12. Hammill A.M., Wentzel M., Gupta A. et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011;57(6):1018-24. doi: 10.1002/pbc.23124
  13. Shirazi F., Cohen C., Fried L., Arbiser J.L. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 2007;5(4):233-6. doi: 10.1089/lrb.2007.1012
  14. Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16(4):525-37. doi: 10.1093/annonc/mdi113
  15. Perry B., Banyard J., McLaughlin E.R. et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007;143(4):504-6. doi: 10.1001/ARCHDERM.143.4.504
  16. Bissler J.J., McCormack F.X., Young L.R. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358(2):140-51. doi: 10.1056/NEJMOA063564
  17. Fernandez K.S., de Alarcon A., Adams D.M., Hammill A.M. Siro- limus for the treatment of juvenile nasopharyngeal angiofibroma. Pediatr Blood Cancer 2020;67(4):e28162. doi: 10.1002/pbc.28162
  18. Calvo A.S., Rochefort J., Javelot M.J. et al. Management of mTOR inhibitors oral mucositis: current state of knowledge. J Oral Med Oral Surg 2019;25(1):11. doi: 10.1051/mbcb/2018027
  19. Roche P.H., Paris J., Regis J. et al. Management of invasive juvenile nasopharyngeal angiofibromas: the role of a multimodality approach. Neurosurgery 2007;61(4):768-77; discussion 777. doi: 10.1227/01.NEU.0000298905.71259.BB
  20. Liu Z., Hua W., Zhang H. et al. The risk factors for residual juvenile nasopharyngeal angiofibroma and the usual residual sites. Am J Otolaryngol 2019;40(3):343-6. doi: 10.1016/j.amjoto.2018.11.010
  21. Pamuk A.E., Ozer S., Suslu A.E. et al. Juvenile nasopharyngeal angiofibroma: A single centre's 11-year experience. J Laryngol Otol 2018;132(11):978-83. doi: 10.1017/S0022215118001779
  22. Thakar A., Gupta G., Bhalla A.S. et al. Adjuvant therapy with flutamide for presurgical volume reduction in juvenile nasopharyngeal angiofibroma. Head Neck 2011;33(12):1747-53. doi: 10.1002/hed.21667
  23. Miller D.D., Gupta A. Histopathology of vascular anomalies: update based on the revised 2014 ISSVA classification. Semin Cutan Med Surg 2016;35(3):137-46. doi: 10.12788/j.sder.2016.053
  24. Beham A., Beham-Schmid C., Regauer S. et al. Nasopharyngeal angiofibroma: true neoplasm or vascular malformation? Adv Anat Pathol 2000;7(1):36-46. doi: 10.1097/00125480-200007010-00006
  25. Sternberg S.S. Pathology of juvenile nasopharyngeal adolescent males angiofibroma; a lesion of adolescent males. Cancer 1954;7(1):15-28. doi: 10.1002/1097-0142(195401)7:1<15::aid-cncr2820070104>3.0.co;2-i
  26. Sun Y., Wu Z. Expression of PCNA, VEGF and bFGF in endothelial cells of juvenile nasopharyngeal angiofibroma. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2006;20(23):1076-8. (In Chinese).
  27. Mishra A., Mishra S.C., Tripathi A.M., Pandey A. Clinical correlation of molecular (VEGF, FGF, PDGF, c-Myc, c-Kit, Ras, p53) expression in juvenile nasopharyngeal angiofibroma. Eur Arch Otorhinolaryngol 2018;275(11):2719-26. doi: 10.1007/s00405-018-5110-5
  28. Ma L., Liu Y., Zhao X. et al. Rapamycin attenuates articular cartilage degeneration by inhibiting β-catenin in a murine model of osteoarthritis. Connect Tissue Res 2019;60(5):452-62. doi: 10.1080/03008207.2019.1583223
  29. Kim T., Tafoya E., Chelliah M.P. et al. Alterations of the MEK/ ERK, BMP, and Wnt/β-catenin pathways detected in the blood of individuals with lymphatic malformations. PLoS One 2019;14(4):e0213872. doi: 10.1371/journal.pone.0213872

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36990 от  21.07.2009.